ValuEngine downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a buy rating to a hold rating in a research note released on Friday.
Other research analysts also recently issued research reports about the company. Stifel Nicolaus downgraded Supernus Pharmaceuticals from a buy rating to a hold rating and set a $47.00 target price on the stock. in a report on Tuesday, September 19th. They noted that the move was a valuation call. Janney Montgomery Scott reiterated a hold rating and set a $47.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Cowen reiterated a positive rating and set a $50.00 target price (up previously from $40.00) on shares of Supernus Pharmaceuticals in a report on Thursday, August 3rd. Piper Jaffray Companies reiterated a hold rating and set a $45.00 target price on shares of Supernus Pharmaceuticals in a report on Friday, September 8th. Finally, Jefferies Group reissued a buy rating and issued a $51.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, September 20th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $49.60.
Shares of Supernus Pharmaceuticals (NASDAQ SUPN) traded down $0.05 during trading hours on Friday, reaching $37.15. The company had a trading volume of 465,400 shares, compared to its average volume of 609,007. Supernus Pharmaceuticals has a 52 week low of $21.50 and a 52 week high of $50.04. The stock has a market cap of $1,906.95, a P/E ratio of 35.09, a PEG ratio of 1.57 and a beta of 1.19.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The firm had revenue of $80.40 million for the quarter, compared to the consensus estimate of $78.74 million. The company’s revenue for the quarter was up 41.5% compared to the same quarter last year. research analysts predict that Supernus Pharmaceuticals will post 1.07 EPS for the current year.
In related news, insider Stefan K.F. Schwabe sold 95,000 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total value of $4,426,050.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Padmanabh P. Bhatt sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $49.86, for a total value of $249,300.00. Following the completion of the transaction, the senior vice president now directly owns 12,500 shares in the company, valued at $623,250. The disclosure for this sale can be found here. Insiders sold a total of 150,000 shares of company stock worth $7,055,350 over the last ninety days. 6.70% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pinebridge Investments L.P. lifted its holdings in shares of Supernus Pharmaceuticals by 1.3% during the 2nd quarter. Pinebridge Investments L.P. now owns 6,624 shares of the specialty pharmaceutical company’s stock valued at $285,000 after buying an additional 86 shares during the period. Arizona State Retirement System lifted its holdings in shares of Supernus Pharmaceuticals by 0.4% during the 2nd quarter. Arizona State Retirement System now owns 26,201 shares of the specialty pharmaceutical company’s stock valued at $1,129,000 after buying an additional 100 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Supernus Pharmaceuticals by 0.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 36,650 shares of the specialty pharmaceutical company’s stock worth $1,579,000 after purchasing an additional 128 shares in the last quarter. CS Mckee LP increased its stake in shares of Supernus Pharmaceuticals by 0.5% in the 2nd quarter. CS Mckee LP now owns 42,050 shares of the specialty pharmaceutical company’s stock worth $1,812,000 after purchasing an additional 200 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Supernus Pharmaceuticals by 0.3% in the 2nd quarter. Rhumbline Advisers now owns 93,907 shares of the specialty pharmaceutical company’s stock worth $4,047,000 after purchasing an additional 288 shares in the last quarter. 98.34% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Supernus Pharmaceuticals (SUPN) Stock Rating Lowered by ValuEngine” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/05/supernus-pharmaceuticals-supn-stock-rating-lowered-by-valuengine.html.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.